Posted October 10, 2014

FDA Warns Consumers of Weight Loss Supplement Containing Undeclared Drugs

On October 10, 2014, the FDA warned consumers not to purchase or use the dietary supplement Sit and Slim II because it was found to contain sibutramine and phenolphthalein.

Sibutramine, the active ingredient in the obesity drug Meridia, was removed from the U.S. market in October 2010 because it can substantially increase blood pressure and pulse rate in some individuals, and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. This drug may also interact, in life-threatening ways, with other medications a consumer may be taking.

Phenolphthalein, once an ingredient in some over-the-counter laxative products, was reclassified by the FDA in 1999 as "not generally recognized as safe and effective."

Sit and Slim II was promoted for weight loss and sold on various websites and in some retail stores.

Consumers who have purchased this supplement should discontinue use immediately and contact their healthcare provider if they have experienced any adverse side effects. Consumers and healthcare providers are also encouraged to report any adverse reactions to the FDA's MedWatch Adverse Event Reporting Program.

See ConsumerLab.com's Review of Weight Loss Supplements for tests of related products.

See Related Warnings:

Two Weight Loss Supplements Found to Contain Drugs

Weight Loss Supplement Contains Undeclared Drug

Weight Loss Supplement Recall Expanded to Include Additional Products

Weight Loss Supplement Containing Drug Recalled

FDA Warns Consumers Of Weight Loss Supplement Containing Undeclared Drug

Weight Loss Supplement Recalled Due To Undeclared Drug

FDA Seizes Weight Loss Supplements Containing Undeclared Drug

Rx Drugs Found in Weight Loss and Enhancement Supplements

Recall of "Slimming" Supplements Spiked with Drug

To read the FDA's warning, use the link below.